Straits Times Index
3,316.68 +8.78 (+0.27%) Nikkei
39,076.45 +459.35 (+1.19%) Hang Seng
18,930.02 -265.58 (-1.38%) FTSE 100
8,370.33 -46.12 (-0.55%) Bitcoin USD
69,437.75 -395.41 (-0.57%) CMC Crypto 200
1,512.46 -13.96 (-0.91%)
ESPR Jan 2026 3.000 put
| Previous close | 1.5100 |
| Open | N/A |
| Bid | 1.4500 |
| Ask | 1.8500 |
| Strike | 3.00 |
| Expiry date | 2026-01-16 |
| Day's range | 1.5100 - 1.5100 |
| Contract range | N/A |
| Volume | |
| Open interest | 17 |
GlobeNewswireFirst-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
– NILEMDO (bempedoic acid), a First-In-Class, Oral Treatment and NUSTENDI (bempedoic Acid / Ezetimibe Fixed-Dose Combination) Receive Label Update Approval from The European Commission as Treatments to Reduce Cardiovascular Risk by Lowering Low-Density Lipoprotein Cholesterol (LDL-C) Levels – – This Makes Bempedoic Acid the First and Only LDL-C Lowering Treatment Indicated for Primary and Secondary Prevention of Cardiovascular Events – – Up To 80% Of Patients Do Not Reach Guideline-Recommended L
- GlobeNewswire
Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
ANN ARBOR, Mich., May 20, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) and Otsuka Pharmaceutical Co., Ltd (Otsuka) announced today that the primary endpoint was achieved in the Phase 3 trial in Japan for bempedoic acid as a potential treatment for patients with hypercholesterolemia. The trial demonstrated statistically significant outcomes on the primary endpoint for bempedoic acid and highlighted its potential future value to patients in Japan. Bempedoic acid, created by Esperion Therapeuti
- GlobeNewswire
Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
ANN ARBOR, Mich., May 14, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that the U.S. Patent and Trademark Office (USPTO) issued a U.S. Patent Term Extension (PTE) certificate for bempedoic acid, which is contained in NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets. The certificate extends the term of U.S. Patent No. 7,335,799 by five years through December 3, 2030. The PTE certificate was granted under the patent restoration provisions
